- Is politics a part of ACEs' exclusion from studies? // Drug Utilization Review;Dec2001, Vol. 17 Issue 12, p92
Reports on the issue on the exclusion of angiotensin-converting enzyme (ACE) inhibitors from the studies on the capability of angiotensin II receptor blockers to slow renal disease. Therapeutic use of ACE inhibitor in patients with Type 1 diabetes; Disadvantage of ACE inhibitors; Reason ACE...
- ARBs: tolerated in patients intolerant to ACE inhibitors. // Reactions Weekly;8/11/2012, Issue 1414, p5
The article discusses research by D. Caldeira and colleagues, published in the "American Journal of Cardiovascular Drugs" on the tolerability of angiotensin receptor blockers (ARBs) in patients who are intolerant to angiotensin-converting enzyme (ACE) inhibitors.
- Why angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not prescribed in the management of hypertension among hemodialysis patients in India. Mateti, Uday Venkat; Nagappa, Anantha Naik; Balkrishnan, Rajesh // Journal of Basic & Clinical Pharmacy;March- May 2014, Vol. 5 Issue 2, p56
A letter to the editor is presented which discusses the advantages of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) among hemodialysis patients.
- ACE inhibitor + ARB therapy: renal toxicity mirrors that seen in RCTs. // Reactions Weekly;4/16/2011, Issue 1347, p3
The article reports on a population-based longitudinal analysis of data from elderly residents of Alberta, Canada which revealed that the hazard ratios for hyperkalaemia and renal dysfunction associated with angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB)...
- Uptake of angiotensin II receptor blockers in the treatment of hypertension. Greving, Jacoba; Denig, Petra; van der Veen, Willem; Beltman, Frank; Sturkenboom, Miriam; de Zeeuw, Dick; Haaijer-Ruskamp, Flora // European Journal of Clinical Pharmacology;Jul2005, Vol. 61 Issue 5/6, p461
Objective: To examine trends in prescribing of angiotensin II receptor blockers (ARBs) as initial and second-line treatment of hypertension. Methods: We performed a cohort study in the Integrated Primary Care Information database, a general practice research database in The Netherlands. We...
- THE JUNE 2003 BARRY M. BRENNER COMGAN LECTURE The future of renoprotection: Frustration and promises. Schieppati, Arrigo; Remuzzi, Giuseppe // Kidney International;Dec2003, Vol. 64 Issue 6, p1947
Considers the prospects for renoprotection, which involves the blockade of angiotensin II with an angiotensin-converting enzyme inhibitor in order to slow the progressive loss of renal function. Growth of the global burden of end-stage renal disease; Mechanisms of progression of renal disease;...
- What is the association of acute renal failure, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in a young patient? Yüksel, Selçuk; Koçyiğit, Ali; Uzun, Ebru; Tepeli, Emre; Özcan, Vefa; Becerir, Tülay // Clinical Kidney Journal;Feb2013, Vol. 6 Issue 1, p98
The article presents an answer to a question on the association of acute renal failure, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in a young patient.
- Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. NAKAMURA, TAKAMICHI; OBATA, JUN-EI; KIMURA, HIDEAKI; OHNO, SHINICHI; YOSHIDA, YOJI; KAWACHI, HIROSHI; SHIMIZU, FUJIO; Nakamura, Takamichi // Kidney International;Mar1999, Vol. 55 Issue 3, p877
Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Background. The renin-angiotensin system is thought to be involved in the progression of glomerulonephritis (GN) into end-stage renal failure (ESRF) because of the...
- Have we fallen off target with concerns surrounding dual RAAS blockade? Lattanzio, Michael R.; Weir, Matthew R. // Kidney International;Sep2010, Vol. 78 Issue 6, p539
A misinterpretation of the results from ONTARGET (Ongoing Telmisartan alone and in combination with ramipril Global Endpoint Trial) has sparked both efficacy and safety concerns within the nephrology community regarding the utilization of dual RAAS blockade to achieve more desirable renal...